Novartis International AG http://www.novartis.com Novartis achieves strong third quarter financial performance and pipeline progress 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1557500.shtml Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531819.shtml Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia 2011-06-16T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1523978.shtml Novartis provides restated consolidated income statement data for 2010 and Q1 2011 following the merger with Alcon; no change to total reported Group data 2011-05-18T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1516687.shtml Novartis makes strong start for the year 2011-04-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1507510.shtml Shareholders approve all proposed resolutions of Novartis Board of Directors 2011-02-22T17:59:22 CET http://www.novartis.com/newsroom/media-releases/en/2011/1491423.shtml Novartis appoints Naomi Kelman as new Head of the Novartis OTC division 2011-02-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1489895.shtml Innovation drives Novartis to double-digit growth for 2010 2011-01-27T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab 2011-01-10T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1478186.shtml Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment 2010-11-17T11:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1463217.shtml Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox®[1] 2010-07-23T17:22:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1433879.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis provides progress-update to achieving 77% majority ownership of Alcon 2010-06-30T22:45:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1428790.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD 2010-04-19T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1404981.shtml Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio 2010-01-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1377026.shtml Novartis réalise, au troisième trimestre, une excellente performance financière et d'importants progrès dans son pipeline 2011-10-25T08:30:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1557501.shtml Novartis enregistre, au deuxième trimestre 2011, d'excellents résultats financiers et quatre homologations majeures 2011-07-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1531820.shtml Résultat opérationnel core en progression de 29% (+30% tcc) à USD 4,2 milliards et marge core en augmentation de 0,4 point de pourcentage (+2,6 points de pourcentage tcc) Novartis entreprend la construction d'un nouveau site ultramoderne de fabrication de produits pharmaceutiques à Saint-Pétersbourg, en Russie 2011-06-16T17:30:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1523979.shtml Novartis démarre l'année en force 2011-04-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1507511.shtml Les actionnaires approuvent l'ensemble des résolutions proposées par le Conseil d'administration de Novartis 2011-02-22T17:59:22+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1491436.shtml Novartis nomme Naomi Kelman directrice de la division Novartis OTC 2011-02-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1489897.shtml Novartis: l'innovation entraîne une croissance à deux chiffres en 2010 2011-01-27T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1482783.shtml Novartis réalise une excellente performance au troisième trimestre: les produits lancés récemment génèrent 20%* du chiffre d'affaires, homologation de Gilenya, consolidation d'Alcon 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1453758.shtml Novartis réalise, au deuxième trimestre, une excellente performance financière, soutenue par l'essor grandissant de l'innovation 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1431808.shtml Novartis: le portefeuille des soins de santé génère une forte croissance au premier trimestre 2010; innovation, croissance et productivité progressent 2010-04-20T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1405507.shtml Novartis a réalisé des résultats records en 2009, porté par l'élan des produits lancés récemment qui dopent la croissance de son portefeuille des soins de santé tout entier 2010-01-26T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1377019.shtml Novartis erzielt im dritten Quartal eine starke finanzielle Performance sowie Fortschritte in der Pipeline 2011-10-25T08:30:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1557502.shtml Novartis erzielt im zweiten Quartal 2011 starke Finanzergebnisse und erreicht vier wichtige Zulassungen 2011-07-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1531821.shtml Novartis beginnt mit dem Bau einer neuen, hochmodernen pharmazeutischen Produktionsanlage in St. Petersburg, Russland 2011-06-16T17:30:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1523980.shtml Novartis startet kraftvoll in das Jahr 2011 2011-04-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1507512.shtml Aktionäre folgen sämtlichen Empfehlungen des Verwaltungsrats von Novartis 2011-02-22T17:59:22+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1491437.shtml Novartis ernennt Naomi Kelman zur neuen Leiterin der OTC-Division von Novartis 2011-02-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1489896.shtml Innovation als treibende Kraft: Novartis erzielt 2010 ein zweistelliges Wachstum 2011-01-27T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1482784.shtml Novartis erzielt im dritten Quartal eine hervorragende Performance: Die jüngsten Produkte steuern 20%* zum Umsatz bei; Gilenya wird zugelassen; Alcon wird konsolidiert 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1453748.shtml Novartis übernimmt die 77%ige Mehrheitsbeteiligung an Alcon und ergänzt ihr führendes Gesundheitsportfolio durch eine neue Wachstumsplattform im Bereich der Augenheilkunde 2010-08-26T11:35:03+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1440553.shtml Gestützt auf eine verstärkte Innovationsdynamik erzielt Novartis im zweiten Quartal eine starke finanzielle Performance 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml Das Gesundheitsportfolio von Novartis erzielt im ersten Quartal 2010 starke Zuwächse - mit Fortschritten bei Innovation, Wachstum und Produktivität 2010-04-20T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1405500.shtml Novartis erzielt 2009 Rekordergebnisse - Neu eingeführte Produkte erweisen sich als Wachstumstreiber 2010-01-26T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1377020.shtml